Adjuvant Cemiplimab Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
Adjuvant therapy with cemiplimab improved DFS vs placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery.
Related Articles
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma
Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.
Overcoming Disparities in Cancer Care
Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care.
Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations
Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.
Study identifies benefits, risks linked to popular weight-loss drugs | WashU Medicine
GLP-1 medications tied to decreased risk of dementia, addiction; increased risk of kidney, pancreas and gastrointestinal problems
Dr Fenske on ASCT Outcomes in MCL After First MRD-Negative CR
Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.
Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
Incidence of Immune-Related Adverse Events With GI Cancers Relatively Low – Oncology Nurse Advisor
Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.
Genetic Testing Considerations and Questions Persist Surrounding Tumor-Agnostic Approvals
Pedro Barata, MD, details factors affecting treatment selection with biomarker-based approvals and highlights questions regarding genetic testing.